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INTRODUCTION
Diffusely infiltrating astrocytomas are the most common
primary brain tumors in adults, being classified into
four grades according to the World Health Organization
(WHO).
1 Glioblastoma (GBM), grade IV astrocytoma, is the
most frequent,
2 and presents median survival rarely
exceeding 12 months in spite of currently available treat-
ment approaches.
3 GBM may manifest rapidly de novo
(primary GBM), or may develop slowly from grade II or
grade III astrocytomas (secondary GBM), suggesting that
they are distinct disease entities that evolve through
different genetic pathways.
In recent genome-wide analyses, high rates of sponta-
neous mutations in the gene encoding cytosolic NADP-
dependent isocitrate dehydrogenase 1 (IDH1) have been
reported in diffuse gliomas including WHO grades II and
III astroglial and oligodendroglial lineages.
4–8 Mutations of
IDH1 are rare in primary GBM (,10%) and frequent
in secondary GBM (.80%).
4–7,9–11 Thus, IDH1 mutations
are strong predictors of more favorable prognosis and a
highly selective molecular marker of secondary GBM that
complements clinical criteria for distinguishing them from
primary GBM. Intriguingly, mutations of IDH1 predomi-
nantly occurred in younger patients and were preferentially
found in tumors harboring TP53 mutations.
12 These results
corroborate the fact that primary and secondary GBMs
originate from different progenitor cells.
IDH1, located on 2q33.3, encodes the cytosolic NADP
+
specific isocitrate dehydrogenase, which catalyzes the
oxidative decarboxylation of isocitrate to a-ketoglutarate.
13
IDH1 is configured as a homodimer with two enzymatically
active sites, and most of its activity is detected in the cytosol
and in peroxisomes. The other four members of the IDH
family are exclusively localized in mitochondria.
14 Glioma-
specific mutations in IDH1 always affect the amino acid
arginine 132 located in an evolutionarily highly conserved
region at the binding site for isocitrate.
11 Mutations in IDH1
are of somatic origin and heterozygous, and inactivate
enzyme activity.
7
We studied the frequency of IDH1 mutations in a series of
161 GBM patients from the Brazilian population according
to patient age, gender, GBM type and survival time.
Tumor samples were collected during surgical proce-
dures by the Neurosurgery Groups of different institutions
from the state of Sa ˜o Paulo: 93 from Hospital das Clı ´nicas,
School of Medicine of University of Sa ˜o Paulo; 38 from
Barretos Cancer Hospital; 13 from Paulista School of
Medicine, Federal University of Sa ˜o Paulo; 10 from Albert
Einstein Jewish Hospital; and 7 from Nove de Julho
Hospital. Informed consent was obtained from each patient,
and the study was approved by the local ethics committee.
The samples included frozen tissues, collected upon
surgical removal and immediately snap-frozen in liquid
nitrogen
15 and paraffin-embedded blocks. The mean age of
161 GBM patients was 56 years, with 59 females and 102
males. A total of 155 cases were primary GBMs (mean age
55 years), and 6 cases were diagnosed as secondary GBM
(mean age 31 years) with histological evidence of a previous
less malignant astrocytoma.
DNA was extracted from the frozen tissues by a standard
phenol/chloroform method or by Trizol (Invitrogen Inc,
Carlsbad, CA, USA), following the manufacturer’s instruc-
tions, and by QiaAmp DNA Micro kit (Qiagen, Hilden,
Germany) from paraffin-embedded sections.
Polymerase chain reaction (PCR) followed by DNA
sequencing was applied to detect IDH1 mutation. Primers
sequences synthesized by IDT (Integrated DNA Techno-
logies, Inc, Coralville, IA, USA) for PCR amplification of
exon 4 were (59-39): CCATCACTGCAGTTGTAGGTT and
CATACAAGTTGGAAATTTCTGG. PCR products were
generated in a 25 mL reaction mixture including 100 ng of
DNA, 50 mM KCl, 50 mM of each dNTP, 10 mM Tris-HCl
(pH 9.0), 1.5 mM MgCl2, 10 pmol of each primer and 1 unit
of Taq DNA polymerase (GE Healthcare, Piscataway, NJ,
USA). The PCR was performed with an initial denaturating
step at 94˚C for 5 min, followed by 35 cycles consisting of
94˚C for 30 s, 54˚C for 30 s and at 72˚C for 30 s. After the final
cycle, an extension period of 10 min at 72˚C was performed.
The PCR products (436 bp) of amplification were checked,
purified with a GFX column (GE Healthcare) and sequenced
on an ABI Prism 3130 DNA automated sequencer using the
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TM Terminator Cycle Sequencing Ready Reaction Kit
version 3.1 (Applied Biosystems, Foster City, CA, USA).
Primers used for the sequencing were the same as those
used for PCR. Results were analyzed and compared with
the public sequence of IDH1 cDNA (GenBank), accession
no. NM_005896.
The statistical analyses and their associations with patient
characteristics were performed by chi-square test (x
2).
Overall survival (OS) was calculated as the interval between
the surgery and day of death, in months. The log-rank test
was used for univariate analysis to estimate differences in
survival time for IDH1 mutation status, according to the
Kaplan–Meier method. Calculations were performed using
STATA, version 7 (STATA Corp., College Station, TX, USA)
and SPSS 15.0 software (SPSS, Chicago, IL, USA), with
statistical significance of p,0.05.
We found IDH1 mutations in 11.8% (19 out of 161) of
samples tested, with a higher mutation rate in GBMs
diagnosed as secondary, 66.7% (4 out of 6), than in cases
of primary GBMs, 9.7% (15 out of 155), p,0.001. All
mutations were heterozygous, located at codon 132, result-
ing in amino acid change from arginine to histidine. We
found a higher frequency of IDH1 mutation in females
(18.6%) than in males (7.8%) (p=0.041). GBM patients
carrying IDH1 mutations were significantly younger (diag-
nosed before age 50 years), mean age of 44 years, than
patients with wild-type IDH1 (diagnosed at age 50 years or
older), mean age of 56 years, p=0.011 (Table 1). The mean
survival time of all GBM patients with and without IDH1
mutations was 12 months (19 cases) and 9 months (142
cases), respectively (p=0.075, log-rank test), as shown in
Figure 1.
DISCUSSION
A higher rate of IDH1 mutation in secondary compared
with primary GBM cases (66.7% vs. 9.7%) was observed in
our study. Additionally, patients carrying IDH1 mutations
were younger (44 years) than those patients without the
mutation (56 years), and IDH1 status has been shown to
have an association trend with an increase in the overall
survival of GBM patients, as described by others.
4–7,9–12 The
lack of statistical impact of the overall survival time might
be attributed to a low number of cases with IDH1 mutation
reflecting a low incidence of secondary GBM in our series.
We have also previously reported a low prevalence of TP53
mutations, usually detected among secondary GBM cases,
because of a higher frequency of primary GBM in our
series.
16 Both results concerning TP53 and IDH1 mutation
status point out the molecular differences between primary
and secondary GBM. These results reinforce the concept
that, despite the histological similarities, primary and
secondary GBMs are genetically and clinically distinct
entities.
6,12
In summary, this study established the frequency of IDH1
mutation in a Brazilian series of GBM, confirmed IDH1
mutation as a genetic marker for secondary GBM, and
therefore as complementary information to help predict the
outcome of patients with GBM.
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Table 1 - IDH1 mutation status of glioblastomas according to age, gender and tumor subtype in Brazilian patients.
IDH1 mutation
Characteristics GBM patients (%) Positive* Negative % p value
161 19 142 11.8
Gender
Female 59 (36.7) 11 48 18.6 0.041
Male 102 (63.3) 8 94 7.8
Age at diagnosis (years)
,50 52 (32.3) 11 41 21.1 0.011
$50 109 (67.7) 8 101 7.3
(Age, mean¡SE) 54.6¡13.4 43.9¡19.1 56.1¡11.9
Tumor subtype
Primary 155 (96.3) 15 140 9.7 ,0.001
Secondary 6 (3.7) 4 2 66.7
*IDH1 mutation at R132H in heterozygous form.
Figure 1 - Survival of glioblastoma patients according to their
IDH1 mutation status (positive vs. negative). Glioblastoma
patients carrying an IDH1 mutation had longer overall survival
(log-rank test; Mantel–Cox test; p=0.075).
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